Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 1/20 | 0.31 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120223 | 0.91 | DPP4 (0.34) | — | |
| SCHEMBL1119579 | 0.90 | BMPR1B (0.32) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL1962713 | 0.90 | BMPR1B (0.34) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL1960445 | 0.89 | ACKR3 (0.36) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL1119545 | 0.85 | BRD4 (0.35) | PIM1PIM3PIM2 | |
| SCHEMBL1962515 | 0.85 | DPP4 (0.34) | MAPK14 | |
| SCHEMBL1120117 | 0.83 | MAPK14 (0.32) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL16456992 | 0.80 | WNT1 (0.31) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL1963189 | 0.78 | BRD4 (0.34) | MAPK14 | |
| SCHEMBL1962175 | 0.78 | GSK3B (0.35) | IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER SCHERING PHARMA AKTIENGESELLESCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | BMPR1B 4775/4885BMPR1A 4644/4885TGFBR1 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.